Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| REPLIMUNE | 11 | 1 | +6,88 % | ||
| GRAIL | 5 | - | -0,57 % | ||
| BIONTECH | 4 | 13 | -0,06 % | ||
| NEUROCRINE BIOSCIENCES | 3 | 17 | -0,45 % | ||
| ALLOGENE THERAPEUTICS | 3 | 6 | -6,53 % | ||
| GILEAD SCIENCES | 3 | 5 | -0,46 % | ||
| C4 THERAPEUTICS | 3 | 5 | -10,27 % | ||
| PROTHENA | 3 | 1 | +0,54 % | ||
| REGENERON PHARMACEUTICALS | 2 | 22 | -1,06 % | ||
| ALKERMES | 2 | 8 | +5,76 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Replimune receives FDA rejection for melanoma treatment | 2 | Investing.com | ||
| Fr | FDA verweigert Zulassung für Replimune-Medikament - Aktie bricht ein | 13 | Investing.com Deutsch | ||
| Fr | Cantor Fitzgerald downgrades Replimune stock rating after second FDA rejection | 1 | Investing.com | ||
| Fr | Replimune: Cantor Fitzgerald stuft Aktie nach zweiter FDA-Ablehnung herab | 1 | Investing.com Deutsch | ||
| Fr | Replimune Group, Inc.: Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma | 1 | GlobeNewswire (USA) | ||
| Fr | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| Fr | Prothena befördert Kingston und Isaacs in die Führungsriege | 1 | Investing.com Deutsch | ||
| Fr | FDA erteilt Mesoblast grünes Licht für zulassungsrelevante DMD-Studie mit Ryoncil | 7 | Investing.com Deutsch | ||
| Fr | Prothena promotes Kingston, Isaacs to leadership roles | 1 | Investing.com | ||
| Fr | FDA clears Mesoblast DMD trial for Ryoncil in children | 13 | Investing.com | ||
| Fr | IDEAYA veröffentlicht am Montag entscheidende Studiendaten zum Aderhautmelanom | 5 | Investing.com Deutsch | ||
| Fr | IDEAYA to report uveal melanoma trial results Monday | 1 | Investing.com | ||
| Fr | Prothena Corporation plc: Prothena Announces Leadership Team Updates | 328 | Business Wire | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| Fr | Allogene Therapeutics, Inc.: Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026 | 2 | GlobeNewswire (USA) | ||
| Fr | Hedge Fund and Insider Trading News: Chris Rokos, Crispin Odey, Bill Ackman, David Tepper, Saba Capital Management, Tudor Investment Corp, Impactive Capital, Grail Inc (GRAL), Amkor Technology Inc (AMKR), and More | 3 | Insider Monkey | ||
| Fr | Intellia Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| Fr | Crinetics Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Solid Biosciences Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Vir Biotechnology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | FDA rejects Replimune's melanoma prospect for second time | 6 | FierceBiotech |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.